- Home
- ASH vs ARQT Comparison
ASH vs ARQT Comparison
Compare ASH & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASH
- ARQT
- Stock Information
- Founded
- ASH 1924
- ARQT 2016
- Country
- ASH United States
- ARQT United States
- Employees
- ASH N/A
- ARQT N/A
- Industry
- ASH Specialty Chemicals
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- ASH Consumer Discretionary
- ARQT Health Care
- Exchange
- ASH Nasdaq
- ARQT Nasdaq
- Market Cap
- ASH 2.4B
- ARQT 2.1B
- IPO Year
- ASH N/A
- ARQT 2020
- Fundamental
- Price
- ASH $47.33
- ARQT $20.74
- Analyst Decision
- ASH Buy
- ARQT Strong Buy
- Analyst Count
- ASH 7
- ARQT 7
- Target Price
- ASH $60.67
- ARQT $19.00
- AVG Volume (30 Days)
- ASH 660.3K
- ARQT 1.9M
- Earning Date
- ASH 11-05-2025
- ARQT 10-28-2025
- Dividend Yield
- ASH 3.51%
- ARQT N/A
- EPS Growth
- ASH N/A
- ARQT N/A
- EPS
- ASH N/A
- ARQT N/A
- Revenue
- ASH $1,869,000,000.00
- ARQT $263,464,999.00
- Revenue This Year
- ASH N/A
- ARQT $72.46
- Revenue Next Year
- ASH $2.82
- ARQT $31.69
- P/E Ratio
- ASH N/A
- ARQT N/A
- Revenue Growth
- ASH N/A
- ARQT 99.50
- 52 Week Low
- ASH $45.21
- ARQT $8.03
- 52 Week High
- ASH $88.89
- ARQT $21.30
- Technical
- Relative Strength Index (RSI)
- ASH 34.36
- ARQT 68.31
- Support Level
- ASH $46.30
- ARQT $16.68
- Resistance Level
- ASH $49.27
- ARQT $21.30
- Average True Range (ATR)
- ASH 1.28
- ARQT 1.00
- MACD
- ASH -0.08
- ARQT 0.25
- Stochastic Oscillator
- ASH 19.63
- ARQT 89.84
About ASH Ashland Inc.
Ashland Inc is a world-wide specialty materials company that serves a wide range of industrial markets. The company has a business-centric operating model and is organized into four distinct segments: life sciences, personal care, specialty additives, and intermediates. Key customers for the firm include pharmaceutical companies and manufacturers of personal care products, food and beverages, and nutraceuticals and supplements. The life sciences segment derives maximum revenue. The company generates its sales from North America, Europe, Asia Pacific, and Latin America, and Others.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.